Quinolones versus macrolides in the treatment of legionellosis: A systematic review and meta-analysis

Journal of Antimicrobial Chemotherapy

Volumn 69, Issue 9, 2014, Pages 2354-2360

  Burdet, C ^a,b   Lepeule, R ^c   Duval, X ^a,b   Caseris, M ^a   Rioux, C ^a   Lucet, J C ^a,b   Yazdanpanah, Y ^a,b  

^a BICHAT HOSPITAL   (France)

^b INSERM   (France)

^c BEAUJON HOSPITAL   (France)

Author keywords

Antimicrobial; Efficacy; Legionnaires' disease

Indexed keywords

AZITHROMYCIN; CIPROFLOXACIN; CLARITHROMYCIN; ERYTHROMYCIN; LEVOFLOXACIN; MACROLIDE; OFLOXACIN; PAZUFLOXACIN; QUINOLONE DERIVATIVE; ROXITHROMYCIN; SPARFLOXACIN; TROVAFLOXACIN; ANTIINFECTIVE AGENT;

ANTIMICROBIAL THERAPY; ARTICLE; ARTIFICIAL VENTILATION; CLINICAL STUDY; CONVALESCENCE; DRUG EFFICACY; EMPYEMA; HUMAN; INTENSIVE CARE UNIT; KIDNEY FAILURE; LEGIONNAIRE DISEASE; LENGTH OF STAY; META ANALYSIS; MONOTHERAPY; MORTALITY; OUTCOME ASSESSMENT; PHLEBITIS; PLEURA EFFUSION; RANDOMIZED CONTROLLED TRIAL (TOPIC); SEPTIC SHOCK; SYSTEMATIC REVIEW; TREATMENT OUTCOME; COMPARATIVE STUDY; COMPLICATION; LEGIONELLOSIS; SURVIVAL;

ANTI-BACTERIAL AGENTS; HUMANS; LEGIONELLOSIS; LENGTH OF STAY; MACROLIDES; QUINOLONES; SURVIVAL ANALYSIS; TREATMENT OUTCOME;

EID: 84905976540     PISSN: 03057453     EISSN: 14602091     Source Type: Journal    
DOI: 10.1093/jac/dku159     Document Type: Article

References (36)

1. Fields BS, Benson RF, Besser RE. Legionella and Legionnaires' disease: 25 years of investigation. Clin Microbiol Rev 2002; 15: 506-26.
2. Blasi F. Atypical pathogens and respiratory tract infections. Eur Respir J 2004; 24: 171-81.
3. Beaute J, Zucs P, de Jong B. Legionnaires' disease in Europe, 2009-2010. Euro Surveill 2013; 18: pii=20417.
4. Greig JE, Carnie JA, Tallis GF et al. An outbreak of Legionnaires' disease at the Melbourne Aquarium, April 2000: investigation and case-control studies. Med J Aust 2004; 180: 566-72.
5. Den Boer JW, Yzerman EP, Schellekens J et al. A large outbreak of Legionnaires' disease at a flower show, the Netherlands, 1999. Emerg Infect Dis 2002; 8: 37-43.
6. Che D, Campese C, Santa-Olalla P et al. Sporadic community-acquired Legionnaires' disease in France: a 2-year national matched case-control study. Epidemiol Infect 2008; 136: 1684-90.
7. Viasus D, Garcia-Vidal C, Di Yacovo S et al. Community-acquired Legionella pneumophila pneumonia: Single-centre experience with 214 hospitalised cases over 15 years. Clin Microbiol Infect 2013; 18: 135.
8. el-Ebiary M, Sarmiento X, Torres A et al. Prognostic factors of severe Legionella pneumonia requiring admission to ICU. Am J Respir Crit Care Med 1997; 156: 1467-72.
9. de Lau LM, Siepman DA, Remmers MJ et al. Acute disseminating encephalomyelitis following Legionnaires' disease. Arch Neurol 2010; 67: 623-6.
10. Antonarakis ES, Wung PK, Durand DJ et al. An atypical complication of atypical pneumonia. Am J Med 2006; 119: 824-7.
11. Daumas A, El-Mekaoui F, Bataille S et al. Acute tubulointerstitial nephritis complicating Legionnaires' disease: a case report. J Med Case Rep 2012; 6: 100.
12. Campese C, Bitar D, Jarraud S et al. Progress in the surveillance and control of Legionella infection in France, 1998-2008. Int J Infect Dis 2011; 15: e30-7.
13. Benin AL, Benson RF, Besser RE. Trends in legionnaires disease, 1980- 1998: declining mortality and new patterns of diagnosis. Clin Infect Dis 2002; 35: 1039-46.
14. Mandell LA, Wunderink RG, Anzueto A et al. Infectious Diseases Society of America/American Thoracic Society consensus guidelines on the management of community-acquired pneumonia in adults. Clin Infect Dis 2007; 44 Suppl 2: S27-72.
15. Lim WS, Baudouin SV, George RC et al. BTS guidelines for the management of community acquired pneumonia in adults: update 2009. Thorax 2009; 64 Suppl 3: iii1-55.
16. Higgins JPT, Green S (eds). Cochrane Handbook for Systematic Reviews of Interventions Version 5.0.2 (Updated September 2009). The Cochrane Collaboration, 2009.
17. Wells G, Shea B, O'Connell D et al. The Newcastle-Ottawa Scale (NOS) for assessing the quality of nonrandomised studies in meta-analyses. http://www.ohri.ca/programs/clinical_epidemiology/oxford.asp (22 January 2014, date last accessed).
18. Dournon E, Mayaud C, Wolff M et al. Comparison of the activity of three antibiotic regimens in severe Legionnaires' disease. J Antimicrob Chemother 1990; 26 Suppl B: 129-39.
19. Lode H, Garau J, Grassi C et al. Treatment of community-acquired pneumonia: a randomized comparison of sparfloxacin, amoxycillinclavulanic acid and erythromycin. Eur Respir J 1995; 8: 1999-2007.
20. Gacouin A, Le Tulzo Y, Lavoue S et al. Severe pneumonia due to Legionella pneumophila: prognostic factors, impact of delayed appropriate antimicrobial therapy. Intensive Care Med 2002; 28: 686-91.
21. Sokol WN Jr, Sullivan JG, Acampora MD et al. A prospective, double-blind, multicenter study comparing clarithromycin extendedrelease with trovafloxacin in patients with community-acquired pneumonia. Clin Ther 2002; 24: 605-15.
22. Fogarty C, Siami G, Kohler R et al. Multicenter, open-label, randomized study to compare the safety and efficacy of levofloxacin versus ceftriaxone sodium and erythromycin followed by clarithromycin and amoxicillinclavulanate in the treatment of serious community-acquired pneumonia in adults. Clin Infect Dis 2004; 38 Suppl 1: S16-23.
23. Blazquez Garrido RM, Espinosa Parra FJ, Alemany Frances L et al. Antimicrobial chemotherapy for Legionnaires' disease: levofloxacin versus macrolides. Clin Infect Dis 2005; 40: 800-6.
24. Querol-Ribelles JM, Tenias JM, Querol-Borras JM et al. Levofloxacin versus ceftriaxone plus clarithromycin in the treatment of adults with community-acquired pneumonia requiring hospitalization. Int J Antimicrob Agents 2005; 25: 75-83.
25. Sabria M, Pedro-Botet ML, Gomez J et al. Fluoroquinolones vs macrolides in the treatment of Legionnaires' disease. Chest 2005; 128: 1401-5.
26. Haranaga S, Tateyama M, Higa F et al. Intravenous ciprofloxacin versus erythromycin in the treatment of Legionella pneumonia. Intern Med 2007; 46: 353-7.
27. Nakamura S, Yanagihara K, Izumikawa K et al. The clinical efficacy of fluoroquinolone and macrolide combination therapy compared with single-agent therapy against community-acquired pneumonia caused by Legionella pneumophila. J Infect 2009; 59: 222-4.
28. Griffin AT, Peyrani P, Wiemken T et al. Macrolides versus quinolones in Legionella pneumonia: results from the Community-Acquired Pneumonia Organization international study. Int J Tuberc Lung Dis 2010; 14: 495-9.
29. Pedro-Botet ML, Yu VL. Treatment strategies for Legionella infection. Expert Opin Pharmacother 2009; 10: 1109-21.
30. Pedro-Botet L, Yu VL. Legionella: macrolides or quinolones? Clin Microbiol Infect 2006; 12 Suppl 3: 25-30.
31. Svanstrom H, Pasternak B, Hviid A. Use of azithromycin and death from cardiovascular causes. N Engl J Med 2013; 368: 1704-12.
32. Shehab N, Patel PR, Srinivasan A et al. Emergency department visits for antibiotic-associated adverse events. Clin Infect Dis 2008; 47: 735-43.
33. Corrao G, Zambon A, Bertu L et al. Evidence of tendinitis provoked by fluoroquinolone treatment: a case-control study. Drug Saf 2006; 29: 889-96.
34. Brown KA, Khanafer N, Daneman N et al. Meta-analysis of antibiotics and the risk of community-associated Clostridium difficile infection. Antimicrob Agents Chemother 2013; 57: 2326-32.
35. Fantin B, Duval X, Massias L et al. Ciprofloxacin dosage andemergence of resistance in human commensal bacteria. J Infect Dis 2009; 200: 390-8.
36. European Centre for Disease Prevention and Control. Legionnaires' Disease in Europe, 2011. http://ecdc.europa.eu/en/publications/Publications/ legionnaires-disease-in-europe-2011.pdf (18 January 2014, date last accessed).